Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 2/20 | 0.40 |
| ▸ | EP300 | Q09472 | 3/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.38 |
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 0.38 |
| ▸ | RNASEL | Q05823 | 8/20 | 0.37 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27222172 | 1.00 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL16287990 | 1.00 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL16288001 | 1.00 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL16287975 | 1.00 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL16287982 | 1.00 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL17991820 | 0.94 | CHAT (0.42) | CHATEP300ENPP1NAA50KAT5 | |
| SCHEMBL16574734 | 0.94 | CHAT (0.36) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL15083455 | 0.93 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL16289137 | 0.93 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL | |
| SCHEMBL16289101 | 0.93 | CHAT (0.40) | CHATEP300ENPP1NAA50RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-03-04 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061860-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CHAT 4808/4885EP300 4472/4885ENPP1 1849/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | CHAT 4808/4885EP300 4472/4885ENPP1 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.